Welcome to Scandivir AB
Scandivir is a joint venture between industry and science, focused on diagnosis, treatment and prevention of virus related diseases.
Scandivir's business concept is to develop simple and rapid diagnostic methods to detect infection with the obesity related virus Adenovirus-36 (Ad-36), and antiviral treatments for Ad-36 and other relevant viruses that cause diseases and problems for humans and animals.
The company's operations is divided into two main areas: Diagnostics and Treatments.
On the diagnostics side, the first objective is to develop a test kit to detect infection with the virus Ad-36, which is likely to be contributing to the global obesity epidemic. An ELISA test for professional users is being prepared for production and commercialization, and the next step is to develop a kit for home use.
On the treatments side, the objective is to develop antiviral treatments for those who find themselves infected with Ad-36, as well as other viruses that affect humans and animals. One interesting example is the virus causing the common cold, against which a patented sea cucumber extract in Scandivir's portfolio has shown promising results in previous studies.
Latest update from Scandivir- October 09
Click at the link below to watch live presentation of latest update from Scandivir R&D, finances and capitalization.(Professor Richard Atkinson is the only oral part of the presentations in English and starts from slide 19. A more extensive presentation in English will be available soon)
http://mindpool.se/projekt/scandivir/scandivir.html
Presentations by:
CEO Anders Struksnes
VP R&D Dan Edwall
Professor Richard Atkinson- VCU and Richmond Biotech Park
Professor Martin Schalling -Karolinska Institute
